Novonesis (Novozymes) B (OTCPK:NVZMF)
$ 60.875 1.133 (1.9%) Market Cap: 28.48 Bil Enterprise Value: 30.18 Bil PE Ratio: 38.65 PB Ratio: 2.42 GF Score: 97/100

Novozymes A/S Extraordinary Shareholders Meeting Transcript

Mar 04, 2024 / 03:00PM GMT
Release Date Price: $57.41 (+0.81%)
Cornelis de Jong;S;Independent Chairman
Novozymes A

/-

Dear shareholders, welcome to this brief Extraordinary Shareholders' Meeting following the completed combination between Novozymes and Chr. Hansen. Now we're joined as one company, Novonesis, the name you see on today's agenda.

The Board of Directors has been looking forward to hosting you here at the newly opened innovation campus in Hørsholm, north of Copenhagen. The campus has been built as a future-oriented center for innovation, knowledge sharing and customer support, especially in food and health, and it truly reflects what we can achieve with this combination. Thank you to everyone here in person and those of you watching the webcast.

In December 2022, 2 strong companies agreed to combine with the ambition of creating a world-leading biosolutions partner. Our shareholders approved the proposed combination at Extraordinary Shareholder Meetings in March 2023. And on the 29th of January this year, the combination was registered by the Danish Business Authority. So yes, the combination is now a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot